SCHEMBL549759

SCHEMBL549759

Cc1c(C23CC4CC(CC(C4)C2)C3)cc(OCC2CO2)c(C23CC4CC(CC(C4)C2)C3)c1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
GLA P06280 1/20 0.42
TSHR P16473 4/20 0.38
TP53 P04637 3/20 0.38
HIF1A Q16665 2/20 0.38
CYP3A4 P08684 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP1A2 P05177 1/20 0.35
PPARG P37231 1/20 0.35
TDP1 Q9NUW8 1/20 0.33
VDR P11473 1/20 0.31
IKBKB O14920 1/20 0.31
IDO1 P14902 1/20 0.30
TDO2 P48775 1/20 0.30
S1PR1 P21453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL548992 0.94 ALDH1A1 (0.41) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL550067 0.94 ALDH1A1 (0.41) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL548847 0.91 ALDH1A1 (0.40) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL550142 0.91 ALDH1A1 (0.41) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL549920 0.89 ALDH1A1 (0.44) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL548993 0.89 ALDH1A1 (0.40) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL549084 0.88 ALDH1A1 (0.37) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL548793 0.88 ALDH1A1 (0.45) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL548915 0.88 ALDH1A1 (0.41) ALDH1A1GLATSHRTP53HIF1A
SCHEMBL549477 0.87 ALDH1A1 (0.46) ALDH1A1GLATSHRTP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110614-B2 Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative IDEMITSU KOSAN CO., LTD. (JP) 2012-02-07 US disclosed
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2010-03-04 US disclosed
EP-2090563-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE ARCN1, RTN3, CHRNA3 ALDH1A1 312/4885GLA 1474/4885TSHR 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.